• +A A A- Change screen font size
  • Keyboard navigation
  • Gray Default Change background color
  • See picture text

For healthy blood pressure and cholesterol levels

Benolea® proved similar to standard hypertensive therapy its ability to decrease blood pressure.

Blood pressure-reducing and lipid-lowering effect of Benolea® (EFLA®943) in stage-1 hypertension. Susalit, E., et al., Phytomedicine 2011, 18, 251-258.

Benolea® lowered blood pressure and LDL-cholesterol in adults with borderline hypertension.

Effect of Benolea® (EFLA®943) in adult twins with mild hypertension. Perrinjaquet-Moccetti, T., et al., Phytotherapy Research 2008, 22, 1239-1242.

Blood Pressure

A clinical trial carried out for 8 weeks in twins with borderline hypertension confirmed a dosage-dependent blood pressure reducing effect for Benolea®. Blood pressure changed significantly within twin pairs: mean systolic difference reached up to 6 mmHg between the control and the 500 mg dose group and up to 13 mmHg between the 500 mg and the 1000 mg dose group. Diastolic differences amount of 5 mmHg, respectively.

In the latest clinical study, Benolea® showed a comparable blood pressure reducing effect in people with mild elevated values (stage 1 hypertension) than a standard anti-hypertensive drug, Captopril. Benolea® also positively influenced the lipid profile of this population and was well tolerated. The blood pressure reduction in the Benolea® group after 8 weeks amounted to about 12 mmHg for systolic and 5 mmHg for diastolic blood pressure, respectively.

Decrease of systolic blood pressure from baseline

Cholesterol level

In a randomized, double-blind, double-dummy, active-controlled clinical trial with 232 volunteers aged 25 to 60 years with stage 1 hypertension (systolic blood pressure 140-159 mmHg, and/or diastolic blood pressure 90-99 mmHg) showed not only a blood pressure reduction but also a significant reduction of total cholesterol and triglycerides levels which was not observed in the anti-hypertensive drug Captopril group.

These findings echo the results of a preliminary study in twins, conducted in Germany which demonstrated a significant dose-dependent reduction of LDL (Low Density Lipoprotein) cholesterol for 500 mg and 1000 mg per day of Benolea® after 8 weeks. Increased levels of LDL are associated with atherosclerosis, and thus heart attack, stroke and peripheral vascular disease. For this reason, LDL cholesterol is often called ‘bad’ cholesterol.

Mode of action >>

Reduction of mean LDL-C concentration compared to baseline, after 4 and 8 weeks of intervention

READ MORE IN OUR PRODUCT FLYER

DOWNLOAD
x

Please fill out the form
to download the file

I have read and agree to the Privacy Statement